Suetemp

Oncology APP

[Suetemp @SusanVTemple]

@rshereme Sold out

[James Martin, SJ @JamesMartinSJ]

“Woe to you who are rich, for you have already received your comfort. Woe to you who are well fed now, for you will go hungry. Woe to you who laugh now, for you will mourn and weep" (Lk 6: 24-6).

[Suetemp @SusanVTemple]

@SBryant79102 @smc429 Clinically and scientifically impossible. Blow a 2cm hole in your hand and see how long it takes to heal. Moronic

[Vic @vic_010100]

How can it be that a company that publicly claims to have withdrawn from Russia continues to supply material to Russia for military purposes, among other things, and to sell it via official partners?
@DuPont_News

🧵18/18

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

1/ Excellent news for 🇺🇸 patients receiving CAR-T therapy!

FDA has listened to data and relaxed CRS monitoring and driving restrictions for liso-cel for #lymsm / ide-cel for #MMsm.

Huge step to lower time toxicity and disparities.

Can this be fixed for all CAR-T products?

[John Streicher @JohnStreicher1]

My NIDA grant renewal is almost 2 months late and I’m going to have to start firing my students and staff. Not a lot of transformation to be had in my lab.

[Suetemp @SusanVTemple]

@DrNeilStone ✋🏻

[Alastair McAlpine, MD @AlastairMcA30]

I thought I would spend my days on Twitter making funny memes and nerding out with fellow medics.

Instead, I’m debunking AI-generated anti-vaxx slop from the head of frikkin Health & Human Sciences. While pointing out that Pubmed searches aren’t evidence.

Astonishing.

[Atul Gawande @Atul_Gawande]

This is a travesty and a nightmare. The US was a founder of @Gavi. It lowers vaccine costs for the world, has vaccinated 1B children, and averted 19M deaths. This pull out will cost 100s of thousands of children's lives a year -- and RFK Jr will be personally responsible.

[Beth Faiman PhD @Bethfaiman]

Hot off the presses! #NCCN guidelines v1.2026 now online, and it’s only 2025! Lots of supportive care and treatment updates for patients with #multiplemyeloma https://t.co/BU2AcbUFM6

[Suetemp @SusanVTemple]

@NickKristof @SecRubio

[Suetemp @SusanVTemple]

@NickKristof @SecRubio - is this who we are now? Letting people - including children -die/economies destroyed?

[Suetemp @SusanVTemple]

@frmattfish @TheHappyPriest Romero

[Vincent Rajkumar @VincentRK]

Just out: Guidelines for testing and reporting cytogenetic results in myeloma @BloodCancerJnl⁩ #OpenAccess Bookmark!

Allows you to incorporate latest IMS/IMWG high risk criteria in practice.
⁦@lbaughn⁩ ⁦@RahulBanerjeeMD⁩ ⁦@Rfonsi1⁩ https://t.co/xzFgvOfpss

[Suetemp @SusanVTemple]

@SouthronHabibi @RichRaho But we are deporting many who are here legally - and we are not following our Constitution by denying due process.

[Suetemp @SusanVTemple]

@BrianLaarh66991 @iamundertow @realDonaldTrump NAFO Tuba division rises to the ‘ahem’ occasion

[Mohamad Mohty @Mohty_EBMT]

Here is my 10-minute summary of the key myeloma highlights from #EHA2025.
Warm congratulations to all the outstanding speakers and investigators. Above all, my deepest gratitude goes to the patients and their families: your courage, trust, and participation are the true driving force behind the remarkable pace of progress toward curing this disease.
@TheIACH @EHA_Hematology @TheEBMT @ASH_hematology
We stand united in our shared mission to heal, to bring hope, and, whenever possible, to eradicate blood diseases. Together, through science, compassion, and passion, we strive for a future where every patient can live free from the burden of these illnesses.

[Vincent Rajkumar @VincentRK]

Key Myeloma therapy update for 2025

1) Newly diagnosed: Start treatment with quads, if possible. (Dara-VRd or Isa-VRd).

2) Auto Transplant: can be deferred for standard risk patients, especially if good response to induction. But collect and store stem cells for future use.

3) Maintenance: Doublet maintenance with Dara/ Len or bortezomib/ Len for high risk myeloma. Either Single or Doublet maintenance for standard risk.

4) Use new IMWG IMS risk stratification

5) First relapse: standard triplet therapy is fine for most. CART in first relapse mainly for functional high risk (progression or early relapse with induction).

6) When using CART, disease burden should be controlled and minimal to reduce risk of serious toxicity.

[Suetemp @SusanVTemple]

@BenDiamondMD @BloodPortfolio Congratulations, Dr. Diamond!

[Suetemp @SusanVTemple]

@NIH @NIHDirector_Jay Bunch of hogwash. Doge/you dismantled and defunded top notch research facilities/programs/scientists. You have zero credibility.